Zim Laboratories files regulatory dossier for approval of Rizatriptan orally dissolving film

08 Jul 2020 Evaluate

Zim Laboratories has filed the regulatory dossier for approval of Rizatriptan orally dissolving film in Europe. Rizatriptan orally dissolving film is a product developed using its Thinoral technology which yields instantly wettable, rapidly dissolving, and stable films.

The product is used in the treatment of migraine which is invariably associated with symptoms like nausea and vomiting. The submission of the Rizatriptan orally dissolving film MAA represents a critical milestone for ZIM and for European patients suffering from Migraine.

Zim Laboratories has established itself as one of the preferred healthcare solution providers in the field of New Drug Delivery Systems (NDDS).

Zim Laboratories Share Price

70.68 -0.47 (-0.66%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×